Jump to content

Human challenge study

From Wikipedia, the free encyclopedia

A human challenge study, also called a challenge trial or controlled human infection model (CHIM), is a type of clinical trial for a vaccine or other pharmaceutical involving the intentional exposure of the test subject to the condition tested.[1][2][3] Human challenge studies may be ethically controversial because they involve exposing test subjects to dangers beyond those posed by potential side effects of the substance being tested.[2][3] Controlled human infection studies are also used to study viruses and immune responses.[4][5]

During the mid 20th and 21st century, the number of human challenge studies has been increasing.[6][7] A challenge study to test promising vaccines for prevention of COVID-19 was under consideration during 2020 by several vaccine developers, including the World Health Organization (WHO),[8][9] and was approved in the UK in 2021.[10]

Over the second half of the 20th and the 21st centuries, vaccines for some 15 major pathogens have been fast-tracked in human challenge studies while contributing toward vaccine development to prevent cholera, typhoid, seasonal flu, and other infections.[11] Since the 1980s, challenge trials which reported about adverse events have had only 0.2% of patients with serious adverse events, and no deaths.[6] According to medical ethicists, methods of conducting clinical trials by human challenge testing have improved over the 21st century to satisfy ethical, safety, and regulatory requirements, becoming scientifically acceptable and ethically valid as long as participants are well-informed and volunteer freely, and the trials adhere to established rigor for conducting clinical research.[2][3][11]

Design

[edit]

The intent of a challenge study is to fast-track the timeline for providing evidence of safety and efficacy of a therapeutic drug or vaccine, especially by compressing (to a few months) the usually lengthy duration of Phase II–III trials (typically, many years).[2][3][12] Following preliminary proof of safety and efficacy of a candidate drug or vaccine in laboratory animals and healthy humans, controlled "challenge" studies may be implemented to bypass typical Phase III research, providing an accelerated path to regulatory approval of the test compound for widespread prevention against an infectious disease, such as COVID-19.[2][9]

The design of a challenge study involves first, simultaneously testing a vaccine candidate for immunogenicity and safety in laboratory animals and healthy adult volunteers (100 or fewer) – which is usually a sequential process using animals first – and second, rapidly advancing its effective dose into a large-scale Phase II–III trial in low-risk, healthy volunteers (such as young adults), who would then be deliberately infected with the disease being tested against for comparison with a placebo control group.[2][3][9] In a challenge study for a vaccine to prevent an infectious disease, participants would be closely monitored for signs of toxicity and adequate immune response, such as by producing substantial levels of antibodies against the virus causing the disease.[2][3][8]

Ethics

[edit]

Awareness of the history of challenge trials is indispensable, including trials that were problematic or even connected to abuse.[13] Special ethical issues can arise when a wealthy country finances and organizes these clinical trials in a less wealthy country.[14]

Two commonly discussed general thresholds for risk to research participant are minimizing all risk after the infection and avoiding serious injury.[15] Researchers typically customize other thresholds for each clinical trial.[15]

Common reasons for participating in human challenge studies include altruism and wishing to contribute to medical progress.[16][17] People who participate in these studies might be more altruistic in general than others, including possibly more likely to contribute to their communities in other ways, such as donating blood.[17]

Vaccines for infections

[edit]

Challenge studies have been used to expedite evaluation of vaccines for several diseases,[3] such as cholera,[18] typhoid fever,[19] malaria,[20] influenza,[1] streptococcal pharyngitis,[21] tuberculosis,[22] shigella,[23] pertussis,[24] and dengue fever.[25]

Other than expediting clinical evaluation of vaccine properties, advantages of using challenge studies for vaccine candidates include minimizing bias which is inherently part of traditional cohort studies, as both the exposure (timing of infection, virus challenge dose) and outcome (assessment of blood biomarkers) are standardized.[20] Disadvantages include high cost of conducting the trial at multiple locations and the complex management of infrastructure for a challenge trial, especially for obtaining national regulatory approval, organizing participants and trial personnel, and implementing laboratories with Good Clinical Laboratory Practice qualifications.[20] Before beginning a challenge study, a vaccine sponsor must have demonstrated Good Manufacturing Practice standards for approval to use the candidate vaccine in humans, including expensive toxicology and immunogenicity testing.[20][26] The vaccine sponsor may have required proof of safety and efficacy of adjuvants for delivering the vaccine, demonstrated what the effective vaccination schedule may be, and coordinated with international regulatory agencies and bioethicists for approval and eventual distribution, all requiring coordinated financing and planning.[20]

COVID-19

[edit]
See also: COVID-19 vaccine clinical research § Trial and authorization status

Human challenge studies were under consideration to hasten the development of a COVID-19 vaccine in the early stages of the pandemic,[3][9][27] including one proposal made by bioethicist Nir Eyal,[2] and another by rubella vaccine inventor Stanley Plotkin with bioethicist Arthur Caplan.[26] These authors propose that the multi-year duration and multinational location of a typical Phase III efficacy clinical trial will continue as usual, while people infected with COVID-19 will continue to suffer or die.[26] As an alternative based on emerging results from COVID-19 vaccine challenge studies, regulatory agencies could allow early emergency use of the vaccine, while the challenge study continues collecting data for eventual licensure.[26]

In May 2020, a guidance document was issued by the WHO on criteria for conducting challenge clinical trials and providing clinical care for the participants.[8] Following the challenge infection with or without the candidate vaccine, volunteers would be monitored closely in hospitals or clinics managed by physicians treating people with COVID-19 disease and with life-saving resources, if needed.[2][3][8] Volunteering for a vaccine challenge study during the COVID-19 pandemic is likened to the emergency service of healthcare personnel for COVID-19-infected people, firefighters, or organ donors.[2][3]

Human SARS-CoV-2 challenge studies have also been conducted to investigate the viral infection and immune response kinetics in COVID-19.[4][5] Unlike patient-based studies, challenge studies provide a unique opportunity to examine the immune system before viral exposure, immediately after exposure, and in individuals who do not become infected upon exposure. These studies have enabled scientists to identify a biomarker for protection and discover that various distinct immune responses precede symptom onset, including some that are also present in individuals who do not become infected upon exposure.[5]

In March 2024, funding for a five-year international consortium to develop and run human challenge studies for mucosal (transmission-blocking) Covid vaccines was announced on behalf of the European Union’s Horizon Europe Programme and the Coalition for Epidemic Preparedness Innovations (CEPI).[28] Called Mucosal Immunity in human Coronavirus Challenge (MusiCC) and led by Imperial College London, trials are planned to take place in the UK, Europe, Singapore, and the United States.[28] Representatives of the consortium and its Scientific Advisory Board met in April 2024 to start the project.[29] At that meeting, a speaker from CEPI said that human challenge studies were a part of the goal of achieving vaccines for new pandemic diseases in 100 days.[29]

References

[edit]
  1. ^ a b Lambkin-Williams, Rob; Noulin, Nicolas; Mann, Alex; Catchpole, Andrew; Gilbert, Anthony S. (22 June 2018). "The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics". Respiratory Research. 19 (1): 123. doi:10.1186/s12931-018-0784-1. ISSN 1465-993X. PMC 6013893. PMID 29929556.
  2. ^ a b c d e f g h i j Eyal N, Lipsitch M, Smith PG (31 March 2020). "Human challenge studies to accelerate coronavirus vaccine licensure". The Journal of Infectious Diseases. 221 (11): 1752–1756. doi:10.1093/infdis/jiaa152. PMC 7184325. PMID 32232474.
  3. ^ a b c d e f g h i j Callaway E (April 2020). "Should scientists infect healthy people with the coronavirus to test vaccines?". Nature. 580 (7801): 17. Bibcode:2020Natur.580...17C. doi:10.1038/d41586-020-00927-3. PMID 32218549. S2CID 256820005.
  4. ^ a b Killingley, Ben; Mann, Alex J.; Kalinova, Mariya; Boyers, Alison; Goonawardane, Niluka; Zhou, Jie; Lindsell, Kate; Hare, Samanjit S.; Brown, Jonathan; Frise, Rebecca; Smith, Emma; Hopkins, Claire; Noulin, Nicolas; Löndt, Brandon; Wilkinson, Tom; Harden, Stephen; McShane, Helen; Baillet, Mark; Gilbert, Anthony; Jacobs, Michael; Charman, Christine; Mande, Priya; Nguyen-Van-Tam, Jonathan S.; Semple, Malcolm G.; Read, Robert C.; Ferguson, Neil M.; Openshaw, Peter J.; Rapeport, Garth; Barclay, Wendy S.; Catchpole, Andrew P.; Chiu, Christopher (May 2022). "Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults". Nature Medicine. 28 (5): 1031–1041. doi:10.1038/s41591-022-01780-9. hdl:10044/1/96278. PMID 35361992. Retrieved 12 April 2024.
  5. ^ a b c Lindeboom, Rik G. H.; Worlock, Kaylee B.; Dratva, Lisa M.; Yoshida, Masahiro; Scobie, David; Wagstaffe, Helen R.; Richardson, Laura; Wilbrey-Clark, Anna; Barnes, Josephine L.; Kretschmer, Lorenz; Polanski, Krzysztof; Allen-Hyttinen, Jessica; Mehta, Puja; Sumanaweera, Dinithi; Boccacino, Jacqueline M. (July 2024). "Human SARS-CoV-2 challenge uncovers local and systemic response dynamics". Nature. 631 (8019): 189–198. Bibcode:2024Natur.631..189L. doi:10.1038/s41586-024-07575-x. ISSN 1476-4687. PMC 11222146. PMID 38898278.
  6. ^ a b Adams-Phipps, Jupiter; Toomey, Danny; Więcek, Witold; Schmit, Virginia; Wilkinson, James; Scholl, Keller; Jamrozik, Joshua; Roestenberg, Meta; Manheim, David (11 October 2022). "A Systematic Review of Human Challenge Trials, Designs, and Safety". Clinical Infectious Diseases. 76 (4): 609–619. doi:10.1093/cid/ciac820. PMC 9938741. PMID 36219704.
  7. ^ Cohen, Jon (18 May 2016). "Studies that intentionally infect people with disease-causing bugs are on the rise". Science. 352 (6288): 882–885. doi:10.1126/science.aaf5726.
  8. ^ a b c d "Key criteria for the ethical acceptability of COVID-19 human challenge studies" (PDF). World Health Organization. 6 May 2020. Retrieved 18 May 2020.
  9. ^ a b c d Cohen, Jon (31 March 2020). "Speed coronavirus vaccine testing by deliberately infecting volunteers? Not so fast, some scientists warn". Science. doi:10.1126/science.abc0006. S2CID 216451224. Retrieved 19 April 2020.
  10. ^ "World's first coronavirus Human Challenge study receives ethics approval in the UK". GOV.UK. Retrieved 18 February 2021.
  11. ^ a b Wade Hemsworth (13 May 2020). "McMaster researcher contributes to WHO guidelines for COVID-19 vaccine testing". McMaster University Medical School, Hamilton, Canada. Retrieved 25 May 2020.
  12. ^ Eric Boodman (13 March 2020). "Coronavirus vaccine clinical trial starting without usual animal data". STAT. Retrieved 19 April 2020.
  13. ^ Metzger, W. G.; Ehni, H.-J.; Kremsner, P. G.; Mordmüller, B. G. (2019). "Experimental infections in humans—historical and ethical reflections". Tropical Medicine & International Health. 24 (12): 1384–1390. doi:10.1111/tmi.13320. ISSN 1365-3156. PMID 31654450.
  14. ^ Gordon, SB; Rylance, J; Luck, A; Jambo, K; Ferreira, DM; Manda-Taylor, L; Bejon, P; Ngwira, B; Littler, K; Seager, Z; Gibani, M; Gmeiner, M; Roestenberg, M; Mlombe, Y; Wellcome Trust CHIM workshop, participants. (2017). "A framework for Controlled Human Infection Model (CHIM) studies in Malawi: Report of a Wellcome Trust workshop on CHIM in Low Income Countries held in Blantyre, Malawi". Wellcome Open Research. 2: 70. doi:10.12688/wellcomeopenres.12256.1. PMC 5627502. PMID 29018841.
  15. ^ a b Binik, Ariella (May 2020). "What risks should be permissible in controlled human infection model studies?". Bioethics. 34 (4): 420–430. doi:10.1111/bioe.12736. PMID 32115747. S2CID 211727412.
  16. ^ Eberts, Jake D; Zimmer-Harwood, Paul; Elsey, James W B; Fraser-Urquhart, Alastair; Smiley, Thomas (14 August 2023). "Volunteering for Infection: Participant Perspectives on a Hepatitis C Virus Controlled Human Infection Model". Clinical Infectious Diseases. 77 (Supplement_3): S224–S230. doi:10.1093/cid/ciad350. PMC 10425139. PMID 37579204. Retrieved 1 May 2024.
  17. ^ a b Marsh, Abigail A.; Magalhaes, Monica; Peeler, Matthew; Rose, Sophie M.; Darton, Thomas C.; Eyal, Nir; Morrison, Josh; Shah, Seema K.; Schmit, Virginia (2 November 2022). "Characterizing altruistic motivation in potential volunteers for SARS-CoV-2 challenge trials". PLOS ONE. 17 (11): e0275823. Bibcode:2022PLoSO..1775823M. doi:10.1371/journal.pone.0275823. PMC 9629635. PMID 36322529.
  18. ^ D, Sinclair; K, Abba; K, Zaman; F, Qadri; PM, Graves (16 March 2011). "Oral vaccines for preventing cholera". The Cochrane Database of Systematic Reviews. 2011 (3): CD008603. doi:10.1002/14651858.CD008603.pub2. PMC 6532691. PMID 21412922.
  19. ^ Waddington, Claire S.; Darton, Thomas C.; Woodward, William E.; Angus, Brian; Levine, Myron M.; Pollard, Andrew J. (1 May 2014). "Advancing the management and control of typhoid fever: A review of the historical role of human challenge studies". Journal of Infection. 68 (5): 405–418. doi:10.1016/j.jinf.2014.01.006. ISSN 0163-4453. PMID 24491597.
  20. ^ a b c d e J, Tuju; G, Kamuyu; Lm, Murungi; Fha, Osier (1 October 2017). "Vaccine candidate discovery for the next generation of malaria vaccines". Immunology. 152 (2): 195–206. doi:10.1111/imm.12780. PMC 5588761. PMID 28646586.
  21. ^ Osowicki, Joshua; Azzopardi, Kristy I.; McIntyre, Liam; Rivera-Hernandez, Tania; Ong, Cheryl-lynn Y.; Baker, Ciara; Gillen, Christine M.; Walker, Mark J.; Smeesters, Pierre R.; Davies, Mark R.; Steer, Andrew C. (13 February 2019). "A Controlled Human Infection Model of Group A Streptococcus Pharyngitis: Which Strain and Why?". mSphere. 4 (1): e00647–18, /msphere/4/1/mSphere647–18.atom. doi:10.1128/mSphere.00647-18. PMC 6374595. PMID 30760615.
  22. ^ McShane, Helen (15 May 2020). "Controlled Human Infection Models: Is it Really Feasible to Give People Tuberculosis?". American Journal of Respiratory and Critical Care Medicine. 201 (10): 1180–1181. doi:10.1164/rccm.201912-2408ED. PMC 7233336. PMID 31904993. S2CID 210041310.
  23. ^ MacLennan, Calman A; Aguilar, Anastazia Older; Steele, A Duncan (9 December 2019). "Consensus Report on Shigella Controlled Human Infection Model: Introduction and Overview". Clinical Infectious Diseases. 69 (Supplement_8): S577–S579. doi:10.1093/cid/ciz886. PMC 6901124. PMID 31816066.
  24. ^ Merkel, Tod J (11 July 2020). "Toward a Controlled Human Infection Model of Pertussis". Clinical Infectious Diseases. 71 (2): 412–414. doi:10.1093/cid/ciz842. PMC 7353834. PMID 31552410.
  25. ^ Rose, Anuradha; Sekhar, Amrita (July 2019). "Bioethics of establishing a CHIM model for dengue vaccine development". International Journal of Infectious Diseases. 84: S74–S79. doi:10.1016/j.ijid.2019.01.013. PMID 30641207.
  26. ^ a b c d Plotkin, Stanley A.; Caplan, Arthur (20 April 2020). "Extraordinary diseases require extraordinary solutions". Vaccine. 38 (24): 3987–8. doi:10.1016/j.vaccine.2020.04.039. PMC 7167540. PMID 32331807.
  27. ^ "UK plan to be first to run human challenge Covid trials". BBC News. 20 October 2020.
  28. ^ a b "Global consortium plans coordinated human challenge studies in hunt for transmission-blocking coronavirus vaccines | CEPI". cepi.net. Retrieved 1 May 2024.
  29. ^ a b "Imperial-led global human challenge consortium kick off ambitious 5-year project | Imperial News | Imperial College London". Imperial News. 24 April 2024. Retrieved 1 May 2024.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Human_challenge_study&oldid=1254335842"